Drug intelligence / Profile preview

clostridia cluster XIVa strain relative blautia sp. 001304935, live

Development stage: Unknown
Lead developer: Vedanta Biosciences
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

clostridia cluster XIVa strain relative blautia sp. 001304935, live is a specific, clonal bacterial strain belonging to the Clostridia Cluster XIVa and the *Blautia* genus. It is a key component of **VE303**, a defined bacterial consortium developed by Vedanta Biosciences for the prevention of recurrent *Clostridioides difficile* infection (rCDI). As a live biotherapeutic product (LBP) constituent, this strain works synergistically with seven other commensal strains to restore the gut microbiota's ecological balance. Its primary mechanism involves providing colonization resistance against *C. difficile* by competing for essential nutrients and producing inhibitory metabolites, such as short-chain fatty acids (SCFAs), which lower luminal pH and directly suppress pathogen growth. VE303 is currently in late-stage clinical development following successful Phase 2 results, representing a standardized alternative to fecal microbiota transplantation.

Other names: Blautia sp. 001304935clostridia cluster XIVa strain relative blautia sp. 001304935

Beyond the preview

Go deeper on clostridia cluster XIVa strain relative blautia sp. 001304935, live.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on clostridia cluster XIVa strain relative blautia sp. 001304935, live.

Explore the full profile